Table 2 Metabolic and signaling pathways affected by statin treatment of MiaPaCa-2 pancreatic cancer cells.
From: Variability in statin-induced changes in gene expression profiles of pancreatic cancer
Path ID | Path name | Cerivastatin | Pitavastatin | Simvastatin | Fluvastatin | Atorvastatin | Lovastatin | Pravastatin | Rosuvastatin |
|---|---|---|---|---|---|---|---|---|---|
False discovery rate (FDR) | |||||||||
hsa00100 | Steroid biosynthesis | — | <10−7 | — | — | — | <10−9 | — | — |
hsa03030 | DNA replication | <10−9 | <10−9 | <10−9 | <10−9 | <10−8 | <10−3 | — | — |
hsa04110 | Cell cycle | <10−9 | <10−9 | <10−8 | <10−9 | <10−9 | <10−6 | — | — |
hsa03040 | Spliceosome | <10−9 | <10−9 | <10−9 | <10−9 | <10−8 | <10−8 | — | — |
hsa03430 | Mismatch repair | <10−9 | <10−9 | <10−5 | — | — | — | — | — |
hsa03440 | Homologous recombination | <10−8 | <10−8 | <10−4 | <10−4 | — | — | — | — |
hsa03020 | RNA polymerase | <10−7 | — | <10−8 | <10−5 | <10−3 | 10−3 | — | — |
hsa04144 | Endocytosis | <10−6 | <10−6 | <10−8 | <10−6 | <10−3 | — | — | — |
hsa00240 | Pyrimidine metabolism | <10−6 | <10−6 | <10−6 | <10−4 | <10−3 | — | — | — |
hsa04146 | Peroxisome | <10−5 | <10−3 | — | <10−3 | — | — | — | — |
hsa03018 | RNA degradation | <10−3 | — | — | — | — | — | — | — |
hsa03010 | Ribosome | — | — | <10−8 | 10−3 | — | <10−3 | — | — |
hsa04010 | MAPK signaling pathway | — | — | <10−4 | — | — | <10−3 | — | — |
hsa04540 | Gap junction | — | — | <10−4 | — | — | — | — | — |
hsa00230 | Purine metabolism | — | — | <10−4 | — | — | — | — | — |
hsa03410 | Base excision repair | — | <10−3 | — | — | — | — | — | — |
